HLS Therapeutics Inc (HLS) - Cash Flow Conversion Efficiency
Based on the latest financial reports, HLS Therapeutics Inc (HLS) has a cash flow conversion efficiency ratio of 0.040x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (CA$2.48 Million ≈ $1.79 Million USD) by net assets (CA$61.74 Million ≈ $44.66 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
HLS Therapeutics Inc - Cash Flow Conversion Efficiency Trend (1996–2024)
This chart illustrates how HLS Therapeutics Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Read how much debt does HLS Therapeutics Inc carry for a breakdown of total debt and financial obligations.
HLS Therapeutics Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of HLS Therapeutics Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Scully Royalty Ltd
NYSE:SRL
|
0.009x |
|
Clarus Corp
NASDAQ:CLAR
|
-0.025x |
|
AleAnna, Inc. Class A Common Stock
NASDAQ:ANNA
|
0.154x |
|
Geodrill Ltd
F:7GD
|
0.108x |
|
Frequency Therapeutics Inc
NASDAQ:KRRO
|
-0.173x |
|
Adda Corporation
TWO:3071
|
0.068x |
|
Ruentex Materials Co Ltd
TW:8463
|
0.186x |
|
EcoFirst Consolidated Bhd
KLSE:3557
|
0.008x |
Annual Cash Flow Conversion Efficiency for HLS Therapeutics Inc (1996–2024)
The table below shows the annual cash flow conversion efficiency of HLS Therapeutics Inc from 1996 to 2024. For the full company profile with market capitalisation and key ratios, see how much is HLS Therapeutics Inc worth.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | CA$71.34 Million ≈ $51.61 Million |
CA$8.00 Million ≈ $5.79 Million |
0.112x | -30.59% |
| 2023-12-31 | CA$97.70 Million ≈ $70.67 Million |
CA$15.79 Million ≈ $11.42 Million |
0.162x | +19.54% |
| 2022-12-31 | CA$125.32 Million ≈ $90.65 Million |
CA$16.94 Million ≈ $12.26 Million |
0.135x | +32.27% |
| 2021-12-31 | CA$160.74 Million ≈ $116.27 Million |
CA$16.43 Million ≈ $11.88 Million |
0.102x | +85.14% |
| 2020-12-31 | CA$169.25 Million ≈ $122.43 Million |
CA$9.34 Million ≈ $6.76 Million |
0.055x | -62.75% |
| 2019-12-31 | CA$178.20 Million ≈ $128.91 Million |
CA$26.41 Million ≈ $19.10 Million |
0.148x | -28.28% |
| 2018-12-31 | CA$158.49 Million ≈ $114.65 Million |
CA$32.75 Million ≈ $23.69 Million |
0.207x | +37.20% |
| 2017-12-31 | CA$180.38 Million ≈ $130.49 Million |
CA$27.17 Million ≈ $19.65 Million |
0.151x | +3562.31% |
| 2016-12-31 | CA$24.97 Million ≈ $18.06 Million |
CA$-108.62K ≈ $-78.58K |
-0.004x | +96.16% |
| 2015-12-31 | CA$26.03 Million ≈ $18.83 Million |
CA$-2.94 Million ≈ $-2.13 Million |
-0.113x | -129.05% |
| 2014-12-31 | CA$46.75 Million ≈ $33.82 Million |
CA$18.21 Million ≈ $13.17 Million |
0.389x | -12.46% |
| 2013-12-31 | CA$40.53 Million ≈ $29.32 Million |
CA$18.03 Million ≈ $13.04 Million |
0.445x | -14.10% |
| 2012-12-31 | CA$40.99 Million ≈ $29.65 Million |
CA$21.23 Million ≈ $15.36 Million |
0.518x | -5.88% |
| 2011-12-31 | CA$32.56 Million ≈ $23.55 Million |
CA$17.92 Million ≈ $12.96 Million |
0.550x | -27.03% |
| 2010-12-31 | CA$33.23 Million ≈ $24.04 Million |
CA$25.06 Million ≈ $18.13 Million |
0.754x | +408.59% |
| 2009-12-31 | CA$35.90 Million ≈ $25.97 Million |
CA$5.32 Million ≈ $3.85 Million |
0.148x | -24.36% |
| 2008-12-31 | CA$28.33 Million ≈ $20.50 Million |
CA$5.55 Million ≈ $4.02 Million |
0.196x | -55.32% |
| 2007-12-31 | CA$50.09 Million ≈ $36.24 Million |
CA$21.98 Million ≈ $15.90 Million |
0.439x | +1816.11% |
| 2006-12-31 | CA$30.72 Million ≈ $22.23 Million |
CA$703.50K ≈ $508.90K |
0.023x | -94.50% |
| 2005-12-31 | CA$30.02 Million ≈ $21.72 Million |
CA$12.50 Million ≈ $9.04 Million |
0.416x | +208.31% |
| 2004-12-31 | CA$18.42 Million ≈ $13.33 Million |
CA$2.49 Million ≈ $1.80 Million |
0.135x | -26.74% |
| 2003-12-31 | CA$26.67 Million ≈ $19.30 Million |
CA$4.92 Million ≈ $3.56 Million |
0.184x | -35.68% |
| 2002-12-31 | CA$24.47 Million ≈ $17.70 Million |
CA$7.01 Million ≈ $5.07 Million |
0.287x | +135.36% |
| 2001-12-31 | CA$24.45 Million ≈ $17.69 Million |
CA$2.98 Million ≈ $2.15 Million |
0.122x | -76.93% |
| 2000-12-31 | CA$12.48 Million ≈ $9.03 Million |
CA$6.59 Million ≈ $4.77 Million |
0.528x | +64.79% |
| 1999-12-31 | CA$14.22 Million ≈ $10.29 Million |
CA$4.56 Million ≈ $3.30 Million |
0.320x | +5033.98% |
| 1998-12-31 | CA$10.01 Million ≈ $7.24 Million |
CA$-64.99K ≈ $-47.01K |
-0.006x | -101.99% |
| 1997-12-31 | CA$16.91 Million ≈ $12.23 Million |
CA$5.52 Million ≈ $3.99 Million |
0.326x | -70.75% |
| 1996-12-31 | CA$8.31 Million ≈ $6.01 Million |
CA$9.27 Million ≈ $6.71 Million |
1.116x | -- |
About HLS Therapeutics Inc
HLS Therapeutics Inc., a specialty pharmaceutical company, acquires and commercializes pharmaceutical products for the treatment of psychiatric disorders, central nervous system, and cardiovascular disease in Canada, the United States, and internationally. The company's lead products include Clozaril, an atypical antipsychotic for management of symptoms of treatment-resistant schizophrenia; and V… Read more